Abstract
Objective: To establish a normal range of birthweight with gestational age (GA) at delivery and examine the contribution of maternal characteristics in defining growth restriction in stillbirths. Methods: In 69,895 normal singleton pregnancies, regression analysis was used to determine the association of birthweight with GA and maternal characteristics. The proportion of 290 stillbirths classified as small for GA depending on inclusion or exclusion of maternal characteristics was determined. Results: In normal pregnancies, there was a polynomial association between birthweight and GA. Birthweight increased with maternal weight, height and parity and was lower in Africans and South Asians than in Caucasians. Birthweight for GA was reduced in antepartum stillbirths (n = 243; p < 0.0001) but not in intrapartum stillbirths (n = 47; p = 0.334). There was no significant difference in the proportion of antepartum stillbirths with birthweight below the 10th percentile when birthweight was corrected for GA only compared to correction for GA and maternal characteristics (53.1 vs. 54.3%). The birthweight was below the 10th percentile in 71.8% of antepartum stillbirths at <32 weeks’ gestation, in 47.2% at 33–36 weeks and in 31.5% at ≥37 weeks. Conclusion: Correction of birthweight for maternal characteristics does not alter the proportion of stillbirths that are small for GA.
Journal Section:
Editor's choice
References
1.
Gardosi J, Chang A, Kalyan B, Sahota D, Symonds EM: Customised antenatal growth charts. Lancet 1992;339:283–287.
[PubMed]
2.
Gardosi J, Mongelli M, Wilcox M, Chang A: An adjustable fetal weight standard. Ultrasound Obstet Gynecol 1995;6:168–174.
[PubMed]
3.
Sahota DS, Kagan KO, Lau TK, Leung TY, Nicolaides KH: Customized birth weight: coefficients and validation of models in a UK population. Ultrasound Obstet Gynecol 2008;32:884–889.
[PubMed]
4.
Robinson HP, Fleming JE: A critical evaluation of sonar ‘crown-rump length’ measurements. BJOG 1975;82:702–710.
5.
Nicolaides KH: Screening for fetal aneuploidies at 11 to 13 weeks. Prenat Diagn 2011;31:7–15.
[PubMed]
6.
Brown MA, Lindheimer MD, de Swiet M, Van Assche A, Moutquin JM: The classification and diagnosis of the hypertensive disorders of pregnancy: statement from the International Society for the Study of Hypertension in Pregnancy (ISSHP). Hypertens Pregnancy 2001;20:IX–XIV.
7.
World Health Organisation: Definition and diagnosis of diabetes mellitus and intermediate hyperglycaemia; report of a WHO/IDF consultation 2006;1–46; http://www.who.int/diabetes/publications/en, accessed September 2011.
8.
Poon LC, Karagiannis G, Staboulidou I, Shafiei A, Nicolaides KH: Reference range of birth weight with gestation and first-trimester prediction of small-for-gestation neonates. Prenat Diagn 2011;31:58–65.
[PubMed]
9.
Altman DG: Construction of age-related reference centiles using absolute residuals. Stat Med 1993;12:917–924.
10.
Zweig MH, Campbell G: Receiver-operating characteristic (ROC) plots: a fundamental evaluation tool in clinical medicine. Clin Chem 1993;39:561–577.
[PubMed]
11.
Gardosi J, Francis A: Customised weight centile calculator – GROW-Centile v.5.12/6.2 2009. Gestation Network, www.gestation.net (v. 5.12:individual; v 6.2:bulk centiles).
12.
Gilbert WM, Young AL, Danielsen B: Pregnancy outcomes in women with chronic hypertension: a population-based study. J Reprod Med 2007;52:1046–1051.
[PubMed]
13.
Murphy HR, Steel SA, Roland JM, Morris D, Ball V, Campbell PJ, Temple RC, East Anglia Study Group for Improving Pregnancy Outcomes in Women with Diabetes (EASIPOD): Obstetric and perinatal outcomes in pregnancies complicated by Type 1 and Type 2 diabetes: influences of glycaemic control, obesity and social disadvantage. Diabet Med 2011;28:1060–1067.
[PubMed]
14.
Yu CK, Khouri O, Onwudiwe N, Spiliopoulos Y, Nicolaides KH, Fetal Medicine Foundation Second-Trimester Screening Group: Prediction of pre-eclampsia by uterine artery Doppler imaging: relationship to gestational age at delivery and small-for-gestational age. Ultrasound Obstet Gynecol 2008;31:310–313.
[PubMed]
15.
Catalano PM, McIntyre HD, Cruickshank JK, McCance DR, Dyer AR, Metzger BE, Lowe LP, Trimble ER, Coustan DR, Hadden DR, Persson B, Hod M, Oats JJ, the HAPO Study Cooperative Research Group: The Hyperglycemia and Adverse Pregnancy Outcome Study: associations of GDM and obesity with pregnancy outcomes. Diabetes Care 2012;35:780–786.
[PubMed]
16.
Centre for Maternal and Child Enquiries (CMACE). 2011. Perinatal Mortality 2009: United Kingdom. London, CMACE.
17.
Lawn JE, Blencowe H, Pattinson R, Cousens S, Kumar R, Ibiebele I, Gardosi J, Day LT, Stanton C, The Lancet’s Stillbirths Series steering committee: Stillbirths: Where? When? Why? How to make the data count? Lancet 2011;377:1448–1463.
18.
Willinger M, Ko CW, Reddy UM: Racial disparities in stillbirth risk across gestation in the United States. Am J Obstet Gynecol 2009;201:469.e1–469.e8.
[PubMed]
19.
Sebire NJ, Jolly M, Harris JP, Wadsworth J, Joffe M, Beard RW, Regan L, Robinson S: Maternal obesity and pregnancy outcome: a study of 287,213 pregnancies in London. Int J Obes Relat Metab Disord 2001;25:1175–1182.
[PubMed]
20.
Stephansson O, Dickman PW, Johansson A, Cnattingius S: Maternal weight, pregnancy weight gain, and the risk of antepartum stillbirth. Am J Obstet Gynecol 2001;184:463–469.
[PubMed]
21.
Syngelaki A, Bredaki FE, Vaikousi E, Maiz N, Nicolaides KH: Body mass index at 11–13 weeks’ gestation and pregnancy complications. Fetal Diagn Ther 2011;30:250–265.
[PubMed]
22.
Aliyu MH, Lynch O, Wilson RE, Alio AP, Kristensen S, Marty PJ, Whiteman VE, Salihu HM: Association between tobacco use in pregnancy and placenta-associated syndromes: a population-based study. Arch Gynecol Obstet 2011;283:729–734.
23.
Chaveeva P, Carbone IF, Syngelaki A, Akolekar R, Nicolaides KH: Contribution of method of conception on pregnancy outcome after the 11–13 weeks scan. Fetal Diagn Ther 2011;30:9–22.
24.
Fretts RC: Etiology and prevention of stillbirth. Am J Obstet Gynecol 2005;193:1923–1935.
[PubMed]
25.
Macintosh MC, Fleming KM, Bailey JA, Doyle P, Modder J, Acolet D, Golightly S, Miller A: Perinatal mortality and congenital anomalies in babies of women with type 1 or type 2 diabetes in England, Wales, and Northern Ireland: population based study. BMJ 2006;333:177.
[PubMed]
26.
Faiz AS, Demissie K, Rich DQ, Kruse L, Rhoads GG: Trends and risk factors of stillbirth in New Jersey 1997–2005. J Matern Fetal Neonatal Med 2012, Epub ahead of print.
27.
Clausson B, Gardosi J, Francis A, Cnattingius S: Perinatal outcome in SGA births defined by customized versus population-based birthweight standards. BJOG 2001;108:830–834.
[PubMed]
28.
McCowan L, Harding JE, Stewart AW: Customized birthweight centiles predict SGA pregnancies with perinatal morbidity. BJOG 2005;112:1026–1033.
[PubMed]
29.
Odibo AO, Francis A, Cahill AG, Macones GA, Crane JP, Gardosi J: Association between pregnancy complications and small-for-gestational-age birth weight defined by customized fetal growth standard versus a population-based standard. J Matern Fetal Neonatal Med 2011;24:411–417.
30.
Ego A, Subtil D, Grange G, Thiebaugeorges O, Senat MV, Vayssiere C, Zeitlin J: Customized versus population-based birth weight standards for identifying growth restricted infants: a French multicenter study. Am J Obstet Gynecol 2006;194:1042–1049.
[PubMed]
31.
Hutcheon JA, Zhang X, Platt RW, Cnattingius S, Kramer MS: The case against customized birthweight standards. Paediatr Perinat Epidemiol 2011;25:11–16.
32.
Akolekar R, Bower S, Flack N, Bilardo CM, Nicolaides KH: Prediction of miscarriage and stillbirth at 11–13 weeks and the contribution of chorionic villus sampling. Prenat Diagn 2011;31:38–45.
[PubMed]
33.
Akolekar R, Syngelaki A, Sarquis R, Zvanca M, Nicolaides KH: Prediction of early, intermediate and late pre-eclampsia from maternal factors, biophysical and biochemical markers at 11–13 weeks. Prenat Diagn 2011;31:66–74.
[PubMed]
34.
Poon LC, Karagiannis G, Staboulidou I, Shafiei A, Nicolaides KH: Reference range of birth weight with gestation and first-trimester prediction of small-for-gestation neonates. Prenat Diagn 2011;31:58–65.
[PubMed]
35.
Karagiannis G, Akolekar R, Sarquis R, Wright D, Nicolaides KH: Prediction of small-for-gestation neonates from biophysical and biochemical markers at 11–13 weeks. Fetal Diagn Ther 2011;29:148–154.
[PubMed]
36.
Greco E, Gupta R, Syngelaki A, Poon LCY, Nicolaides KH: First trimester screening for spontaneous preterm delivery with maternal characteristics and cervical length. Fetal Diagn Ther 2012;31:154–161.
37.
Nicolaides KH: Turning the pyramid of prenatal care. Fetal Diagn Ther 2011;29:183–196.
[PubMed]
38.
Bujold E, Roberge S, Lacasse Y, Bureau M, Audibert F, Marcoux S, Forest JC, Giguère Y: Prevention of preeclampsia and intrauterine growth restriction with aspirin started in early pregnancy: a meta-analysis. Obstet Gynecol 2010;116:402–414.
[PubMed]
39.
Roberge S, Villa P, Nicolaides K, Giguère Y, Vainio M, Bakthi A, Ebrashy A, Bujold E: Early administration of low dose aspirin for the prevention of preterm and term pre-eclampsia: a systematic review and meta-analysis. Fetal Diagn Ther 2012;31:141–146.
[PubMed]
© 2012 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2012
You do not currently have access to this content.
